Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Birmex (Laboratorios de Biológicos y Reactivos de México) produces a polyvalent anti-scorpion venom serum. It is an equine-derived antivenom consisting of F(ab')2 antibody fragments. It is designed to neutralize the toxins of scorpions, specifically those of the genus *Centruroides*, which are prevalent in Mexico. The mechanism involves the binding and neutralization of venom components (neurotoxins) in the bloodstream, preventing them from reaching their targets (ion channels). It is used for the treatment of scorpion envenomation, particularly in pediatric populations where the risk of severe systemic toxicity is higher.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on scorpion antivenom (equine).